3 June 2026 in Arthroscopy, Sports Medicine, and Rehabilitation
Purpose: To develop and implement a simulation‐based arthroscopy curriculum for orthopaedic surgery interns to be completed during their required orthopaedic intern skills month and to evaluate its effectiveness, feasibility, and impact on resident confidence. Methods: Twenty‐one first year residents prospectively completed arthroscopic skill evaluation using VirtaMed augmented reality surgical simulator for the Fundamentals of Arthroscopy Surgical Training (FAST), shoulder, and knee models. Participants then completed the self‐confidence score for surgical trainees survey. Then, they completed simulation training modules on each model over the course of their 1‐month intern skills rotation. Each module contained 13‐14 exercises. Following training, skill evaluations were repeated for each module and self‐confidence survey was repeated. Results: One hundred percent of eligible participants were enrolled, and 100% completed the curriculum. Participant performance improved for all 3 modules (FAST, knee, shoulder). In the FAST modules, pretest to posttest scores for image centering improved from 64.1% to 95.5% ( P < .001), and triangulation and probing improved from 73.5% to 88.4% ( P = .019). In the knee modules, performance improved on diagnostic arthroscopy from 49.9% to 88.8% ( P = .003) and on loose body removal from 40.0% to 75.3% ( P < .001). In the shoulder modules, performance improved on the diagnostic arthroscopy from 89.9% to 98.9% ( P = .011) and for loose body removal from 77.8% to 95.2% ( P = .002). Self‐confidence scale improved from 15.4 to 21.2 ( P < .001). Acceptability of intervention measure, intervention appropriateness measure, and feasibility of intervention was 4.8, 4.6, and 4.7 respectively. Total self‐paced time to completion was 4.9 h for all 3 sections. The shoulder took the most time (1.8 hours), followed by the knee (1.6 hours) and FAST (1.5 hours). Conclusions: The proposed arthroscopy simulation curriculum showed improvement in speed and skill on the arthroscopy simulator and improved personal confidence for orthopaedic surgery interns. It was able to be completed in less than 5 hours with 100% completion rate. Clinical Relevance: Arthroscopy is an essential skill for orthopaedic surgery residents. High‐fidelity simulation is effective at teaching these skills in a safe and controlled environment.
5 November 2026 in The American Journal of Sports Medicine
Background: This randomized controlled trial evaluated the 12-month outcomes of a single intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF), prepared and administered during the same clinical encounter, for the treatment of moderate-to-severe knee osteoarthritis (OA). Purpose/Hypothesis: To evaluate the efficacy of a single intra-articular injection of 25 million autologous adipose-derived SVF cells for moderate-to-severe knee OA, compared with placebo, at 12 months. The authors hypothesized that SVF-treated patients would demonstrate a significantly greater responder rate based on prespecified clinically meaningful improvements in pain and function derived from composite outcomes of the index and contralateral knees. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: Adults aged 35 to 85 years with symptomatic unilateral or bilateral knee OA were eligible if the index knee demonstrated a Western Ontario and McMaster Universities Osteoarthritis Index pain score of ≥8, an Outerbridge grade of 2 to 4 on magnetic resonance imaging (MRI), and a Kellgren-Lawrence grade of 2 to 4 on radiographs. Autologous adipose-derived SVF was prepared using a point-of-care isolation system during the same clinical encounter, assessed against predefined release criteria, and administered as a single intra-articular injection into the index knee. MRI of the index knee was obtained at baseline and at 12 months. Results: A total of 618 participants were assessed for eligibility, of whom 114 were randomized (SVF, n = 83; placebo, n = 31). At 12 months, a single intra-articular injection of 25 million SVF cells demonstrated statistical superiority over placebo for the primary composite clinical endpoint. The responder rate was 51.8% (43/83) in the SVF group compared with 29% (9/31) in the placebo group (difference, 22.8% [95% CI, 3.5%-42%]; 1-sided P = .0149). No serious investigational device-related adverse events were reported. Conclusion: A single intra-articular injection of 25 million autologous adipose-derived SVF cells resulted in statistically superior and clinically meaningful improvements in pain and function at 12 months compared with placebo, with no serious investigational device-related adverse events reported. Registration: IDE 16734; ClinicalTrials.gov NCT04440189.